AMBULATORY INFUSION CENTER MARKET ANALYSIS

Ambulatory Infusion Center Market Size and Trends

The global ambulatory infusion center market is estimated to be valued USD 47.1 Bn in 2024 and is expected to reach USD 95.2 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031.

To learn more about this report, Request sample copy

The ambulatory infusion center market is expected to witness significant growth during the forecast period. The development of technologically advanced infusion pumps, rising prevalence of chronic diseases such as cancer and Crohn's disease requiring long-term treatment therapies, and growing preference for outpatient care are major trends contributing to the market growth. Ambulatory infusion centers offer convenience and lower care costs by transitioning routine care traditionally provided in the inpatient setting to outpatient facilities. This trend is expected to continue as infusion therapies advance and healthcare costs remain high, boosting the demand for efficient ambulatory infusion services.

Rising Prevalence of Cancer and Chronic Diseases

With the changing lifestyle patterns across the globe, the prevalence of various chronic and life-threatening diseases has increased manifolds in the past few decades. Two of the major disease categories pushing the need for ambulatory infusion services are cancer and other chronic diseases. As per various research studies and reports by healthcare organizations, cancer has now emerged as one of the leading causes of mortality worldwide. Just in the U.S., an estimated 1.8 million new cancer cases are diagnosed and over 606,000 cancer deaths occur annually. While some cancer types can be treated with oral medication, many advanced cases require photopheresis, chemotherapy, hydration, or pain management which can only be provided through IV infusions administered on an outpatient basis. Additionally, the rise in risk factors like smoking, obesity, and physical inactivity has also led to a surge in chronic health conditions like diabetes, cardiovascular diseases, autoimmune disorders, and others. All these chronic diseases may also need long term infusion therapy to stabilize the condition or to improve the quality of life. The growing prevalence of cancer and chronic diseases is thus driving more patients towards outpatient ambulatory infusion centers where they can receive specialized treatments in a relaxed setting while continuing with their daily routines. For instance, in February 2024, updated worldwide cancer burden estimates for 2022 were released by the WHO's International Agency for Research on Cancer (IARC) in February 2024, ahead of World Cancer Day. These figures included 20 million new cases and 9.7 million deaths. According to a WHO survey, there is inadequate coverage of cancer care and palliative services under universal health care in many countries. These findings highlight significant inequities and emphasize the need for prompt action to advance these services.

To learn more about this report, Request sample copy

Advancements in Specialized Biologics and Targeted Therapies

Over the last decade, there have been unprecedented advancements in drug development, resulting in a variety of new biologics, immunotherapies, and targeted treatment options. Unlike conventional chemotherapy which aims to destroy fast-dividing cells, these new generation therapies are highly specialized and focus on specific molecular targets associated with certain types of cancers and chronic diseases. While effective, many such biologics including monoclonal antibodies, stem cell therapies, and gene therapies can only be administered intravenously. Therefore, to benefit from these complex and cutting-edge IV-based therapies, patients routinely require long-term or lifetime infusion access in an ambulatory setting. This allows for the convenient administration of treatments at flexible timings over extended periods without disrupting daily activities or work schedule. The approvals of a growing number of targeted biologics coupled with oncology research exploring new infusion-based combinations is fueling the need for expanded outpatient infusion facilities across the globe. This has become a major driver responsible for the significant rise in demand for ambulatory infusion services worldwide.